The immunogenicity, protective efficacy and safety of BBG2Na, a subunit respiratory syncytial virus (RSV) vaccine candidate, against RSV-B

By Power U.F.   Plotnicky H.   Blaecke A.   Nguyen T.N.  

Vaccine, Vol. 22, Iss. 2, 2003-12 ,pp. : 168-176

Elsevier

Access to resources Recommend Favorite

Evaluation of subunit vaccines against feline immunodeficiency virus infection

By Stam J.G.   Verschoor E.J.   Willemse M.J.   van Vliet A.L.W.   Pouwels H.   Chalmers S.K.   Horzinek M.C.   Sondermeijer P.J.A.   Hesselink W.   de Ronde A.  

Vaccine, Vol. 14, Iss. 4, 1996-03 ,pp. : 285-289

Elsevier

Access to resources Recommend Favorite

Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice

By Wu S.-F.   Liao C.-L.   Lin Y.-L.   Yeh C.-T.   Chen L.-K.   Huang Y.-F.   Chou H.-Y.   Huang J.-L.   Shaio M.-F.   Sytwu H.-K.  

Vaccine, Vol. 21, Iss. 25, 2003-09 ,pp. : 3919-3929

Elsevier

Access to resources Recommend Favorite

Nanogram quantities of a DNA vaccine protect rainbow trout fry against heterologous strains of infectious hematopoietic necrosis virus

By Corbeil S.   LaPatra S.E.   Anderson E.D.   Kurath G.  

Vaccine, Vol. 18, Iss. 25, 2000-06 ,pp. : 2817-2824

Elsevier

Access to resources Recommend Favorite

Protection against oronasal challenge with virulent feline leukaemia virus lasts for at least 12 months following a primary course of immunisation with Leukocell&unknown; 2 vaccine

By Harbour D.A.   Gunn-Moore D.A.   Gruffydd-Jones T.J.   Caney S.M.A.   Bradshaw J.   Jarrett O.   Wiseman A.  

Vaccine, Vol. 20, Iss. 23, 2002-07 ,pp. : 2866-2872

Elsevier

Access to resources Recommend Favorite